Scholarlink

<p>Cushing’s disease (CD) is a severe systemic metabolic disorder caused by elevated levels of cortisol sustained by a pituitary neuroendocrine tumor. Endoscopic trans-sphenoidal surgery (ETS) is the first-line treatment, but does not achieve disease remission in all patients. For patients with persistent or recurrent Cushing’s disease, stereotactic radiosurgery (SRS) has been reported as an effective treatment option. This review and meta-analysis assesses the available evidence to systematically highlight the current strengths and limitations of SRS in the treatment of CD. In May 2025, following the PRISMA 2020 statement, a systematic review of Pubmed, Scopus, and Ovid was performed. Of 687 articles screened, 9 were considered eligible, describing a population of 341 patients. Most patients (90%) underwent a single dose of Gamma Knife SRS. The tumor control rate was 97.4% (95% CI: 95.2–99.6%). After a mean follow-up of 61.5 months after the latest SRS cycle, biochemical remission was achieved in 67.1% (95% CI: 58.5–75.7%) of cases in a mean time of 26.4 months. Recurrence post-SRS remission was documented in 21% of cases after a mean time of 39 months. New-onset hypopituitarism was observed in 29.9% of cases, visual impairment and other cranial nerve dysfunction in 1.8% (95% CI: 0.2–3.4%), and 1.9% (95% CI: 0.1–3.7%), respectively. No cases of radionecrosis were seen. After a single cycle of treatment, SRS effectively controls the disease in about half of patients affected by persistent or recurrent CD, with a low percentage of post-treatment complications. Based on the available literature, SRS emerges as a safe and effective treatment, and its implementation in common clinical practice may play a relevant role in the management of CD. Nevertheless, prospective and standardized studies are needed to thoroughly assess its real potential.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiosurgery in recurrent and persistent Cushing’s Disease: a Systematic Review and Meta-Analysis

  • 期刊论文

  • 发表日期：

    2026年1月24日

查看全文
  • Federico Valeri,
  • Vincenzo Mastropasqua,
  • Giuseppe Maria Della Pepa,
  • Gianluca Trevisi,
  • Alessandro Olivi,
  • Ciro Mazzarella,
  • Sabrina Chiloiro,
  • Antonio Bianchi,
  • Liverana Lauretti,
  • Rosalinda Calandrelli,
  • Vincenzo Valentini,
  • Francesco Miccichè,
  • Giuseppe Minniti,
  • Francesco Doglietto,
  • Pier Paolo Mattogno

摘要

Cushing’s disease (CD) is a severe systemic metabolic disorder caused by elevated levels of cortisol sustained by a pituitary neuroendocrine tumor. Endoscopic trans-sphenoidal surgery (ETS) is the first-line treatment, but does not achieve disease remission in all patients. For patients with persistent or recurrent Cushing’s disease, stereotactic radiosurgery (SRS) has been reported as an effective treatment option. This review and meta-analysis assesses the available evidence to systematically highlight the current strengths and limitations of SRS in the treatment of CD. In May 2025, following the PRISMA 2020 statement, a systematic review of Pubmed, Scopus, and Ovid was performed. Of 687 articles screened, 9 were considered eligible, describing a population of 341 patients. Most patients (90%) underwent a single dose of Gamma Knife SRS. The tumor control rate was 97.4% (95% CI: 95.2–99.6%). After a mean follow-up of 61.5 months after the latest SRS cycle, biochemical remission was achieved in 67.1% (95% CI: 58.5–75.7%) of cases in a mean time of 26.4 months. Recurrence post-SRS remission was documented in 21% of cases after a mean time of 39 months. New-onset hypopituitarism was observed in 29.9% of cases, visual impairment and other cranial nerve dysfunction in 1.8% (95% CI: 0.2–3.4%), and 1.9% (95% CI: 0.1–3.7%), respectively. No cases of radionecrosis were seen. After a single cycle of treatment, SRS effectively controls the disease in about half of patients affected by persistent or recurrent CD, with a low percentage of post-treatment complications. Based on the available literature, SRS emerges as a safe and effective treatment, and its implementation in common clinical practice may play a relevant role in the management of CD. Nevertheless, prospective and standardized studies are needed to thoroughly assess its real potential.